These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 7533456)
21. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106 [TBL] [Abstract][Full Text] [Related]
22. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725 [TBL] [Abstract][Full Text] [Related]
23. Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men. Han JH; Choi NY; Bang SH; Kwon OJ; Jin YW; Myung SC; Chang IH; Kim TH; Ahn SH Urology; 2008 Oct; 72(4):749-54; discussion 754-5. PubMed ID: 18701153 [TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Carter HB; Pearson JD; Waclawiw Z; Metter EJ; Chan DW; Guess HA; Walsh PC Urology; 1995 Apr; 45(4):591-6. PubMed ID: 7536366 [TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Lee AK; Levy LB; Cheung R; Kuban D Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415 [TBL] [Abstract][Full Text] [Related]
26. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. Witherspoon LR; Lapeyrolerie T J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931 [TBL] [Abstract][Full Text] [Related]
27. Reliability analysis of first and second generation PSA assays. Wymenga LF; Groenier K; Visser-van Brummen P; Marrink J; Mensink HJ Can J Urol; 2000 Aug; 7(4):1070-6. PubMed ID: 11109077 [TBL] [Abstract][Full Text] [Related]
28. Pitfalls in interpreting prostate specific antigen velocity. Kadmon D; Weinberg AD; Williams RH; Pavlik VN; Cooper P; Migliore PJ J Urol; 1996 May; 155(5):1655-7. PubMed ID: 8627846 [TBL] [Abstract][Full Text] [Related]
29. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764 [TBL] [Abstract][Full Text] [Related]
31. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Piironen T; Pettersson K; Suonpää M; Stenman UH; Oesterling JE; Lövgren T; Lilja H Urology; 1996 Dec; 48(6A Suppl):81-7. PubMed ID: 8973706 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. Vessella RL; Noteboom J; Lange PH Clin Chem; 1992 Oct; 38(10):2044-54. PubMed ID: 1382897 [TBL] [Abstract][Full Text] [Related]
33. Comparability of serum prostate-specific antigen measurement between the hybritech Tandem-R and Abbott AxSYM assays. Leewansangtong S; Goktas S; Lepoff R; Holthaus K; Crawford ED Urology; 1998 Sep; 52(3):467-9. PubMed ID: 9730462 [TBL] [Abstract][Full Text] [Related]
34. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Semjonow A; Köpke T; Eltze E; Pepping-Schefers B; Bürgel H; Darte C Clin Biochem; 2010 Jul; 43(10-11):926-8. PubMed ID: 20450900 [TBL] [Abstract][Full Text] [Related]
35. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. Arcangeli CG; Smith DS; Ratliff TL; Catalona WJ J Urol; 1997 Dec; 158(6):2182-7. PubMed ID: 9366340 [TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen levels in young white and black men 20 to 45 years old. Preston DM; Levin LI; Jacobson DJ; Jacobsen SJ; Rubertone M; Holmes E; Murphy GP; Moul JW Urology; 2000 Nov; 56(5):812-6. PubMed ID: 11068308 [TBL] [Abstract][Full Text] [Related]
37. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Woodrum D; French C; Shamel LB Urology; 1996 Dec; 48(6A Suppl):33-9. PubMed ID: 8973697 [TBL] [Abstract][Full Text] [Related]
38. Abbott IMx evaluated for assay of prostate-specific antigen in serum. Dnistrian AM; Schwartz MK; Smith CA; Nisselbaum JS; Fair WR Clin Chem; 1992 Oct; 38(10):2140-2. PubMed ID: 1382898 [TBL] [Abstract][Full Text] [Related]
39. Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method. Brawer MK; Bankson DD; Haver VM; Petteway JC Prostate; 1997 Mar; 30(4):269-73. PubMed ID: 9111605 [TBL] [Abstract][Full Text] [Related]
40. Reduced stability of prostate-specific antigen after long-term storage of serum at -20 degrees C. Leinonen J; Stenman UH Tumour Biol; 2000; 21(1):46-53. PubMed ID: 10601841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]